Targeting NAD+ Metabolism: Preclinical Insights into Potential Cancer Therapy Strategies

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Nicotinamide adenine dinucleotide (NAD+) is crucial for cellular functions, synthesized mainly via the NAMPT salvage pathway.
• NAD+ consuming enzymes like PARPs and sirtuins are vital for DNA repair and chromatin remodeling.
• Cancer cells alter energy metabolism, impacting NAD+ levels and making them vulnerable to NAD+ depletion strategies.

Purpose of the Study:

• To investigate the therapeutic potential of targeting the NAMPT enzyme in cancer treatment.
• To evaluate the efficacy and toxicity of novel NAMPT inhibitors.

Main Methods:

• Utilizing NAMPT inhibitors to deplete cellular NAD+ levels.
• Assessing the impact of NAMPT inhibition on cancer cell viability and tumor burden.
• Clinical evaluation of a novel NAMPT inhibitor, KPT-9274.

Main Results:

• NAMPT inhibition, alone or combined with other therapies, decreases cancer cell viability and tumor burden.
• Previous NAMPT inhibitors faced toxicity issues, leading to discontinuation.
• The novel NAMPT inhibitor KPT-9274 demonstrates promising efficacy with low toxicity in ongoing clinical trials.

Conclusions:

• Targeting NAMPT represents a viable strategy for cancer therapy by modulating NAD+ metabolism.
• KPT-9274 is a promising low-toxicity NAMPT inhibitor with potential for clinical application in oncology.